Try adjusting your type
14th October, 2009
European Survey on Standards of Care in paediatric oncology centres. J. R. Kowalczyk, M. Samardakiewicz, K. Pritchard-Jones, R. Ladenstein, S. Essiaf, E. Fitzgerald, G. Petrarulo, G. Vassal - EJC , Volume 61, pp 11-19
8th December, 2014
The purpose of this website is to provide good and clear information about the long-term effects of childhood cancer and to refer to the various late-effects outpatient clinics (LATER outpatient clinics) that exist in the Netherlands.
8th September, 2015
Cancer in young people is rare, but it is still a major health issue in Europe. Each year, more than 6,000 young people in Europe die of cancer. There are more than 300,000 European childhood cancer survivors (in 2020, they will be nearly half a million): two-thirds of them have some late side effects of treatment, that are severe and impact on the daily life of half of those affected.
Oligodendroglioma is a type of brain tumor arising from oligodendrocytes, cells that produce myelin – an insulating layer around neurons. This slow-growing tumor generally affects adults and is often found in the frontal lobe of the brain. Symptoms include persistent headaches, seizures, and changes in personality or mental capacity. Treatment typically involves surgery, chemotherapy, and radiation therapy.
In the intricate world of neuro-oncology, oligodendroglioma occupies a unique niche. This distinct type of brain tumor, which originates within the oligodendrocytes or the cells, responsible for producing myelin, has been the subject of significant medical interest due to its rare incidence and unique attributes.
Despite the gravity of the disease, numerous misconceptions surround oligodendroglioma, often leading to unwarranted anxiety and inaccurate assumptions. This article will set out to debunk such myths whilst providing a comprehensive understanding of oligodendroglioma, including its cause, diagnosis, treatment, and future prospects.
The discovery of oligodendroglioma goes back to the early 20th century when Bailey and Cushing, renowned pathologists recognized it as a unique entity, thereby introducing it to the field of neuropathology. Since then, our understanding of this tumor has notably evolved, significantly impacting its diagnosis and treatment.
Oligodendrogliomas are brain tumors that originate from oligodendrocytes, which are a type of glial cell that forms the myelin sheath around nerve fibers. These tumors are defined by their “fried egg” appearance upon histological examination, with individual cells showcasing a clear halo around a centralized nucleus.
Oligodendrogliomas make up approximately 4% of all primary brain tumors, predominantly affecting young to middle-aged adults. These tumors are typically slow-growing, with a predilection for the frontal and temporal lobes of the cerebrum.
Oligodendrogliomas are classified under the World Health Organization (WHO) grading system, under two categories: Grade II (low-grade, slower development) and Grade III (anaplastic oligodendroglioma, with faster growth and higher recurrence potential).
Although the exact cause of oligodendrogliomas remains unknown, research has identified certain genetic abnormalities that frequently manifest in these tumors, suggesting a genetic predisposition.
Studies to determine the influence of environmental factors on oligodendroglioma continue, yet no definitive correlations have been confirmed. This ongoing research considers potential influences including exposure to radiation and organic solvents.
Oligodendrogliomas are more common among adults aged between 40 and 50. While the incidence is slightly higher in males than females, this gender disparity is less pronounced compared to other types of primary brain tumors.
Common symptoms of oligodendroglioma include headaches, seizures, personality changes, and symptoms related to increased intracranial pressure. However, the exact clinical presentation can vary depending on the tumor’s location and size.
Some patients present unique symptoms such as visual impairment and speech difficulties, depending on where the tumor is located. Additional, less common symptoms can include memory deficits, motor weakness, and cognitive impairment.
Traditionally, diagnosis of oligodendroglioma involves imaging studies like CT scans and MRIs, which provide detailed pictures of the brain. A neurological examination is also conducted to assess motor and sensory skills, balance and coordination, mental status and changes in mood or behaviour.
In the modern era, more advanced diagnostic options like spectroscopy, functional MRI, and PET scans are being utilized to get a more comprehensive view of the tumor. These advancements aid in planning the treatment strategy.
Genetic testing provides valuable insight into the specific alterations present in each individual tumor. These alterations can be instrumental in determining the most effective treatment plan and predicting the potential course and outcome of the disease.
The treatment plan for oligodendroglioma is typically multifaceted, involving surgery, radiation therapy, and chemotherapy. The choice of treatment depends on various factors, including the tumor’s grade and location, and the patient’s overall health and personal preferences.
Surgeons aim to remove as much of the tumor as possible while avoiding damage to healthy brain tissue. In some cases, the tumor’s location or size may limit the extent of surgical removal, leading to alternative or additional treatments.
When surgery isn’t possible, or as an adjuvant treatment, radiation therapy and chemotherapy are valuable options. Radiation therapy uses high-energy beams to kill tumor cells, while chemotherapy employs drugs to eliminate cancer cells or restrict their growth.
While these treatments can often effectively control the growth of the tumor, they are not without side effects. Fatigue, cognitive changes, and hair loss are common, and some patients may experience long-term effects on their daily life. Therefore, quality of life considerations always play a pivotal role in treatment decisions.
The survival rate of oligodendroglioma patients is variable, largely dependent on factors such as age, tumor grade, and extent of surgical resection. For example, the 5-year survival rate for patients with a low-grade tumor is relatively higher than that for patients diagnosed with anaplastic oligodendroglioma.
A diagnosis of oligodendroglioma can leave patients facing considerable emotional and psychological challenges. Depression, anxiety, and feelings of loss of control are not uncommon. Comprehensive healthcare should extend beyond physical health to include emotional support and counseling for patients and families.
Despite the challenges oligodendroglioma presents, there is cause for hope. Advances in genetic studies have led to a new understanding of these tumors, opening avenues for targeted treatments. Additionally, immunotherapy and gene therapy offer promising future treatment options.
This meticulously comprehensive discussion of oligodendroglioma should notably overthrow any misconceptions while paving the way to informed discussions about the disease. Fundamentally, the importance of awareness and early detection cannot be overstated, as these are instrumental in determining the course of the disease.
The survival rate varies based on numerous factors, including age, tumor grade, and treatment course. Generally, the 5-year survival rate for low grade oligodendroglioma is commendable, but the figures decrease for high-grade tumors.
Because the causes of oligodendroglioma are still not completely understood, and since it is not a lifestyle disease, there are currently no specific ways to prevent the tumor. However, general health maintenance and monitoring of symptoms can lead to early detection and improved outcomes.
Grade II oligodendrogliomas are considered low-grade, meaning they grow slower and are less aggressive. Grade III tumors, also known as anaplastic oligodendrogliomas, grow quickly and spread more aggressively. This often results in a worse prognosis.
The impact on daily life will vary from patient to patient and is dependent on the location and severity of the tumor. Common symptoms such as headaches, seizures, and cognitive changes can significantly disrupt a patient’s day-to-day activities and overall quality of life.
While successful treatment can effectively control the growth of the tumor, there is still a risk of recurrence, especially in high-grade tumors. Thus, regular follow-ups and imaging studies are necessary.
Share it
You might also like
Option B: Facing Adversity, Building Resilience, and Finding Joy
In 2015 Sheryl Sandberg’s husband, Dave Goldberg, died suddenly at the age of forty-eight. Sandberg and her two young children were devastated, and she was certain that their lives would never have real joy or meaning again.
When Breath Becomes Air By Paul Kalanithi
This inspiring, exquisitely observed memoir finds hope and beauty in the face of insurmountable odds as an idealistic young neurosurgeon attempts to answer the question What makes a life worth living?
The Emperor of All Maladies: A Biography of Cancer
An award-winning exploration of cancer's intricate history and humanity's relentless fight against it. From ancient origins to modern breakthroughs, Siddhartha Mukherjee's Pulitzer Prize-winning book reveals the captivating, inspiring, and sometimes sobering tale of 'The Emperor of All Maladies.'
Cancer: 50 Essential Things to Do: 2013 Edition
The ground-breaking classic guide to surviving cancer—now completely updated!
Wherever You Go, There You Are: Mindfulness Meditation in Everyday Life
Its message, rooted in the art of mindfulness, encourages individuals to live fully in the present moment. With gentle yet profound insights, the book teaches us to be fully present in our lives, regardless of our surroundings or situations.
Radical Acceptance: Embracing Your Life With the Heart of a Buddha
Within the pages of "Radical Acceptance," readers discover a profound message: the affirmation of our complete selves. Tara Brach gently guides us to recognize and embrace every facet of our being—the light and the shadow, the joy and the sorrow.
